Neurocrine Biosciences, Inc. annual operating income for fiscal 2025 was $636 million, an increase of 9.2% from $583 million in fiscal 2024. All figures are reported results from public filings — no estimates or projections.
| Operating Income (annual) | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Operating Income (EBIT) | $636M | $583M | $395M | $249M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Operating Income (quarterly) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Operating Income (EBIT) | $186M | $228M | $239M | $146M | $24M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More NBIX metrics: Revenue · Gross Profit · Net Income · EPS · Free Cash Flow
All NBIX financial statements → Interactive NBIX charts →
About TickerBase · Data methodology & sources